301673-16-5

Basic information

• Product Name: 3-HYDROXYMETHYL-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 2-(HYDROXYMETHYL)-4-N-TERT-BUTOXYCARBONYL-PIPERAZINE;4-N-BOC-2-HYDROXYMETHYLPIPERAZINE;3-(HYDROXYMETHYL)-1-PIPERAZINE CARBOXYLIC ACID, 1,1-DIMETHYLETHYL ESTER;3-HYDROXYMETHYL-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1-Boc-3-hydroxymethyl-piperazine;N-BOC-3-HYDROXYMETHYLPIPERAZINE;1-N-BOC-3-HYDROXYMETHYLPIPERAZINE;tert-Butyl 3-(hydroxymethyl)piperazine-1-carboxylate
• CAS NO: 301673-16-5
• Molecular Formula: C₁₀H₂₀N₂O₃
• Molecular Weight: 216.28
• Product Categories: pharmacetical;Piperaizine
• Mol File: 301673-16-5.mol

Chemical Properties

• Melting Point: 93.0 to 97.0 °C
• Boiling Point: 322.884 °C at 760 mmHg
• Flash Point: 149.075 °C
• Appearance: /
• Density: 1.085 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.478
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 14.97±0.10(Predicted)
• CAS DataBase Reference: 3-HYDROXYMETHYL-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3-HYDROXYMETHYL-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(301673-16-5)
• EPA Substance Registry System: 3-HYDROXYMETHYL-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(301673-16-5)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 301673-16-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Hydroxymethyl-piperazin-1-carboxylic acid tert-butyl ester is used as a building block for the synthesis of various drugs due to its structural properties that facilitate the creation of diverse medicinal compounds.
Used as a Reagent in Chemical Reactions:
In the realm of chemical synthesis, 3-Hydroxymethyl-piperazin-1-carboxylic acid tert-butyl ester is utilized as a reagent, capitalizing on its stability and controlled reactivity to participate in a range of chemical processes.
Used as a Solubility Enhancer in Drug Formulation:
3-Hydroxymethyl-piperazin-1-carboxylic acid tert-butyl ester is employed as a solubility enhancer in the formulation of poorly soluble drugs, improving their bioavailability and therapeutic effectiveness.

InChI:InChI=1/C10H20N2O3/c1-10(2,3)15-9(14)12-5-4-11-8(6-12)7-13/h8,11,13H,4-7H2,1-3H3

Upstream product

• 129799-08-2 tert-butyl methyl piperazine-1,3-dicarboxylate 
• 143540-05-0 2-hydroxymethylpiperazine-1,4-dicarboxylic acid di-tert-butyl ester 
• 183742-29-2 piperazine-1,3-dicarboxylic acid 1-tert-butyl ester 3-ethyl ester 
• 935544-47-1 tert-butyl 3-oxotetrahydro-1H-oxazolo[3,4-a]pyrazine-7(3H)-carboxylate 

Downstream Products

• 317365-33-6 1-(benzyloxycarbonyl)-2-hydroxymethyl-4-(tert-butyloxycarbonyl)-piperazine 
• 85155-83-5 (4-methylpiperazin-2-yl)methanol 

Relevant articles and documents

HETEROAROMATIC DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF

Disclosed are heteroaryl derivatives, pharmaceutical composition and uses in the manufacture of a medicine for treating respiratory diseases, especially for chronic obstructive pulmonary disease (COPD).

Tricyclic heterocyclic compound and use thereof

The present invention provides a tricyclic heterocyclic compound having a serotonin 5-HT2C receptor activation action and the like. A 5-HT2C receptor activator containing a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.

NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF

Disclosed are novel piperazine derivatives that act as agonists of the α7 nAChR. Also disclosed are phannaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds.

Xanthine derivatives as DPP-IV inhibitors

The present invention provides novel compounds exhibiting an excellent DPPIV inhibition effect. The compounds are represented by the formula: wherein, m is 0 or 1; n is 0; R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, and R42 each represent a hydrogen atom; X represents an alkynyl group, an aryl group, and such, which group may be substituted; and, R1 and R2 each independently represents a hydrogen atom, an alkyl group, an alkoxyl group, or such, or salts or hydrates thereof.

Aminoquinazolines and their use as medicaments

Compounds of the formula having an inhibitory effect on signal transduction mediated by tyrosine kinases, their use in the treatment of diseases, especially tumoral diseases and diseases of the lungs and air-ways, and the preparation thereof

Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them

Bicyclic heterocycles of general formula wherein: Ra to Rd, A to C and X are as defined herein, the tautomers, the stereoisomers and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for treating diseases, particularly tumoral diseases, diseases of the lungs and respiratory tract, and the preparation thereof.